CancerNetwork·

Targeting KRAS in Pancreatic Cancer: What is Daraxonrasib’s Mechanism of Action?

Targeting KRAS in Pancreatic Cancer: What is Daraxonrasib’s Mechanism of Action?

Asfar Azmi, PhD, discusses the tricomplex mechanism of daraxonrasib and its impact on overall survival for patients with pancreatic cancer.

You are reading a snippet

Read the full article on CancerNetwork

Open on CancerNetwork

Originally published by CancerNetwork

More from Health